CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia
2 Views
administrator
07/01/23
Dr Jordan Gauthier gives a press conference at ASH 2018 about the comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-Cells alone or in combination with ibrutinib for relapsed and/or refractory chronic lymphocytic leukaemia (CLL).
Watch his interview with ecancer here:
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
Show more
Facebook Comments
No comments found